Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
19 Février 2009 - 4:00PM
PR Newswire (US)
PITTSBURGH, Feb. 19 /PRNewswire-FirstCall/ -- Mylan Inc.
(NASDAQ:MYL) today announced that its Vice Chairman and CEO Robert
J. Coury will preside over the NASDAQ Stock Market opening on
Friday, Feb. 20 from 9:15 to 9:30 a.m. ET. Coury will ring the
opening bell to celebrate the company's switch from The New York
Stock Exchange (NYSE) to NASDAQ. Mylan's common stock began trading
on NASDAQ Dec. 29, 2008. The company is listed on the NASDAQ Global
Select Market, and its common stock continues to trade under the
"MYL" ticker symbol. Mylan's mandatory convertible preferred stock
and 1.25% convertible notes also moved to NASDAQ with the ticker
symbols "MYLNP" and "MYLNG," respectively. Feed Information - The
Opening Bell is available from 9:20 to 9:35 a.m. on Galaxy 19 C/15,
downlink frequency 4000 vertical. The feed can also be found on
Ascent fiber 1623. Technical questions should be directed to Jolene
Libretto at 646-441-5220. Radio Feed - An audio transmission of the
Opening Bell is also available from 9:20 to 9:35 a.m. on uplink IA6
C band / transponder 24, downlink frequency 4180 horizontal. The
feed can be found on Ascent fiber 1623 as well. Webcast - A live
webcast of the NASDAQ Opening Bell will be available at:
http://www.nasdaq.com/reference/marketsite_about.stm. Photos - To
obtain a hi-resolution photograph of the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on
the market open of your choice. About Mylan Mylan Inc., which
provides products to customers in more than 140 countries and
territories, ranks among the leading diversified generic and
specialty pharmaceutical companies in the world. The company
maintains one of the industry's broadest -- and highest quality --
product portfolios, supported by a robust product pipeline; owns a
controlling interest in the world's third largest active
pharmaceutical ingredient manufacturer; and operates a specialty
business focused on respiratory and allergy therapies. For more
information, please visit http://www.mylan.com/. DATASOURCE: Mylan
Inc. CONTACT: Michael Laffin of Mylan Inc., +1-724-514-1968, or
NASDAQ, Jolene Libretto, +1-646-441-5220 Web Site:
http://www.mylan.com/
Copyright